Hematopoietic Cell Transplantation for Miscellaneous Solid Tumors in Adults
Customize your policy alerts
Sign up for Capital Bluecross Policy MP 9.048 alerts
Get alerted when Policy MP 9.048 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage of autologous and allogeneic hematopoietic cell transplantation (HCT) for a list of adult solid tumor types and applies to Capital BlueCross products subject to benefit variations.
No material clinical or coverage changes in this revision.
Coverage Criteria for Hematopoietic Cell Transplantation
Investigational / Not Medically Necessary for listed solid tumors
Autologous or allogeneic HCT is considered investigational for the following adult malignancies (insufficient evidence to support benefit):
Policy states insufficient evidence to support a general conclusion of benefit; see rationale summarizing RCTs, phase 2 studies, and registry data that did not demonstrate consistent survival benefit.
Allogeneic HCT — insufficient evidence / not covered for listed tumors
Allogeneic hematopoietic cell transplantation (allo-HCT) for the following tumors has insufficient evidence:
Based on limited case series; relevant outcomes include overall survival, disease-specific survival, and treatment-related mortality and morbidity.
This policy does not address hematopoietic cell transplantation (HCT) for ovarian cancer, germ cell tumors, ependymoma, malignant glioma, or breast cancer. Those indications are covered by separate policies or are otherwise not addressed in this document; see related policy references for specific guidance.
Allogeneic hematopoietic cell transplantation (allo-HCT) for the miscellaneous solid tumors listed in this policy is considered investigational and not covered. Procedures and services billed using the codes enumerated in the coding section for these indications are subject to denial as investigational and not covered.
Autologous or allogeneic HCT is considered investigational (not medically necessary) for the adult solid tumor types listed in this policy (including, but not limited to, lung cancer, colorectal cancer, pancreatic cancer, renal cell carcinoma, nasopharyngeal cancer, soft tissue sarcomas, thyroid tumors, thymic tumors, tumors of unknown primary, and malignant melanoma) due to insufficient evidence of improved health outcomes. Procedures associated with these investigational indications and the procedure codes listed in the coding section are therefore not covered for these diagnoses.
Coding — Procedure and Billing Codes
Provider Actions, Prior Authorization, and Claims
Check prior authorization per member product
Verify prior authorization requirements with the member's specific plan before scheduling or performing HCT, because coverage and prior authorization requirements vary by product and program (e.g., FEP PPO follows the FEP medical policy manual).
- Confirm whether the member's product requires prior authorization for hematopoietic cell transplantation and related services.
- If the member is FEP PPO, follow the FEP medical policy manual at fepblue.org for authorization rules.
Verify benefits and authorize listed procedure codes
Confirm member benefits and obtain any required authorizations for the procedure codes listed in this policy; several codes are identified as investigational and not covered for miscellaneous solid tumors and may be denied if billed without appropriate authorization.
Step-therapy not specified — confirm with plan
This policy does not specify step therapy requirements; do not assume step-therapy pathways are in effect based on this document alone — check the member's plan for any step-therapy rules.
Claims subject to member benefit and medical necessity review
Claims are paid according to the member's benefit program, eligibility on the date of service, and medical necessity determination; final claim processing is based on the contract that applies to the member's benefit program.
- Ensure documentation supports medical necessity per the member's contract before claim submission.
- Be aware that this policy is not a guarantee of coverage or payment and claims may be denied if services are not medically necessary or are excluded by the member's benefit plan.
Document product-specific benefit variations
Document and verify product-specific applicability before providing or billing for HCT: this policy applies only to certain programs and products administered by Capital Blue Cross and is subject to benefit variations.
- Check for program/product exceptions and follow the applicable product-specific policy (e.g., consult the FEP medical policy manual for FEP PPO members).
- Include the member's product identifier in authorization and benefit-verification requests.
Verify coding and coverage — code list not exhaustive
Before submitting claims, verify that the codes used accurately reflect services rendered and recognize that the policy's code list may not be all‑inclusive; identification of a code in the policy does not itself indicate coverage.
- Use the member's benefit information to determine coverage for listed or unlisted codes.
- Contact Provider Services or Member Services for coding/coverage questions when a code is not clearly covered by the member's benefit plan.
Investigational indications — risk of denial
Be aware claims for autologous or allogeneic HCT billed for the adult solid tumor indications listed in this policy are at risk for denial as investigational; procedures identified as investigational are considered not covered for these indications.
- If treating one of the listed malignancies (e.g., lung, colon, pancreatic, renal cell, soft tissue sarcoma, melanoma, etc.), obtain benefit verification and consider alternative therapies because HCT is deemed investigational for these tumors.
- Do not expect routine coverage for services billed under the policy's investigational codes—these services may be denied as not covered.
Background — Hematopoietic Cell Transplantation Overview
Hematopoietic cell transplantation (HCT) is the infusion of hematopoietic stem cells to restore bone marrow function after marrow‑toxic therapy. Autologous HCT uses the patient’s own harvested stem cells, avoiding donor‑derived tumor contamination. Allogeneic HCT uses cells from a donor with a different genetic constitution and requires donor–recipient HLA compatibility; it carries the potential advantage of a graft‑versus‑tumor effect but also the risks associated with graft‑versus‑host disease and the need for posttransplant immunosuppression. Nonmyeloablative allogeneic approaches have been explored to harness donor‑derived alloreactivity against metastatic solid tumors, but their benefit for the tumor types addressed in this policy remains unproven.
Definitions
Evaluation Requirements and Preapproval
Conduct transplant evaluation; no preapproval checklist provided
Perform standard transplant evaluation activities (for example, HLA typing and donor matching) as part of clinical workup, but note that the policy does not provide an explicit preapproval evaluation checklist.
- Policy describes general evaluation concepts (HLA matching, donor verification) but offers no specific preapproval checklist.
Center and Accreditation Requirements
No center accreditation or volume requirements specified
Recognize that the policy discusses transplant-related concepts but does not specify center accreditation, volume, or other center-specific requirements in this portion of the document.
- Center-level requirements (accreditation or procedural volume) are not defined in the policy text provided.
Post-Transplant Coverage Considerations
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.